KB-1173

Vorsetuzumab

12183

Home » Vorsetuzumab

Background of Vorsetuzumab

CD70 is a type II transmembrane protein, which is mainly expressed in activated T cells, B cells, natural killer (NK) cells, and dendritic cells. Vorsetuzumab is a monoclonal antibody targeting CD70 and can kill tumor cells through antibody-dependent cell-mediated cytotoxicity (ADCC). In addition, vorsetuzumab can also be conjugated with small molecular antitumor drugs to form a new type of targeted therapeutic molecules with accurate targeting and greater lethality.

Specifications

Catalog Number	KB-1173
Antibody Name	Vorsetuzumab
Isotype	Human-IgG1, kappa
FC Muations	Wild Type
Target	CD70
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C;Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Jacobs, J.; Deschoolmeester, V.; Zwaenepoel, K.; Rolfo, C.; Silence, K.; Rottey, S.; Lardon, F.; Smits, E.; Pauwels, P. (2015). CD70: An emerging target in cancer immunotherapy. Pharmacology & Therapeutics, S016372581500145X.
Jin, Linchun; Ge, Haitao; Long, Yu; Yang, Changlin; Chang, Yifan (Emily); Mu, Luyan; Sayour, Elias J.; De Leon, Gabriel; Wang, Qiong J.; Yang, James C.; Kubilis, Paul S.; Bao, Hongbo; Xia, Songsong; Lu, Dunyue; Kong, Yingjun; Hu, Li; Shang, Yujiao; Jiang, Chencheng; Nie, Jing; Li, Shimin; Gu, Yunhe; Sun, Jiahang; Mitchell, Duane A.; Lin, Zhiguo; Huang, Jianping (2017). CD70, a novel target of CAR-T-cell therapy for gliomas. Neuro-Oncology.